Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 5:95:100635.
doi: 10.1016/j.curtheres.2021.100635. eCollection 2021.

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis

Dhan Bahadur Shrestha  1 , Pravash Budhathoki  2 , Yub Raj Sedhai  3 , Ramkaji Baniya  4 , Casey A Cable  5 , Markos G Kashiouris  5 , Dave L Dixon  6 , Jason M Kidd  7 , Yuvraj Adhikari  8 , Anupama Marasini  8 , Shakar Bhandari  8
Affiliations
Review

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis

Dhan Bahadur Shrestha et al. Curr Ther Res Clin Exp. .

Abstract

Background: Patiromer and sodium zirconium cyclosilicate (SZC) are newer options for hyperkalemia treatment. This systematic review and meta-analysis were conducted to assess the safety and side effect profile of patiromer and SZC compared with placebo or other standards of care in the management of hyperkalemia.

Methods: We searched electronic databases for relevant articles. The screening was performed independently and data were extracted among the selected studies. We performed a statistical analysis on Revman 5.4 software. The odds ratio (OR) was used for outcome estimation with a 95% CI.

Results: Patiromer had lower rates of hyperkalemia (OR = 0.44; 95% CI, 0.22-0.89) compared with standard of care. The analysis showed no significant differences between the 2 groups in terms of overall adverse effects, any serious/specific adverse effects, or treatment discontinuation as a result of adverse effects. Comparing the SZC-10 group with standard of care showed no significant differences in the occurrence of hyperkalemia during treatment, overall adverse effects, any serious/specific adverse effects, or treatment discontinuation as a result of adverse effects but showed a higher rate of edema in the treatment group (OR = 6.77; 95% CI, 1.03-44.25). Similarly, no significant differences were seen between the 2 SZC doses for the occurrence of any adverse effects, hyperkalemia, constipation, diarrhea, or urinary tract infection, whereas edema was higher among patients receiving SZC-10 (OR = 3.13; 95% CI, 1.19-8.27).

Conclusions: In patients with acute hyperkalemia, SZC is the drug of choice due to its more rapid reduction of serum potassium level, whereas in patients with chronic hyperkalemia, patiromer appears to be the drug of choice because SZC is associated with an increase in edema, likely due to an increase in sodium absorption, which could have important adverse consequences in patients with chronic kidney disease and or heart failure. Thus, both drugs were found to be safe while treating hyperkalemia. (Curr Ther Res Clin Exp. 2021; 82:XXX-XXX).

Keywords: hyperkalemia; patiromer; potassium; sodium zirconium cyclosilicate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cochrane ROB 2.0 for bias assessment.
Figure 2
Figure 2
Preferred reporting items for systematic reviews and meta-analyses flow diagram.
Figure 3
Figure 3
Forest plots comparing adverse effects between patiromer and placebo group.
Figure 4
Figure 4
Forest plots comparing commonly adverse effects between patiromer and placebo group.
Figure 5
Figure 5
Forest plots comparing adverse effects between sodium zirconium cyclosilicate (SZC)-10 and placebo group.
Figure 6
Figure 6
Forest plots comparing commonly adverse effects between SAC-10 and placebo group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yusuf A.A., Hu Y., Singh B., Menoyo J.A., Wetmore J.B. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study. Am J Nephrol. 2016;44(3):179–186. doi: 10.1159/000448341. - DOI - PubMed
    1. Elliott M.J., Ronksley P.E., Clase C.M., Ahmed S.B., Hemmelgarn B.R. Management of patients with acute hyperkalemia. CMAJ. 2010;182(15):1631–1635. doi: 10.1503/cmaj.100461. - DOI - PMC - PubMed
    1. Harel Z., Harel S., Shah P.S., Wald R., Perl J., Bell C.M. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review. Am J Med. 2013;126(3) doi: 10.1016/j.amjmed.2012.08.016. 264.e9-264.e24. - DOI - PubMed
    1. Veltassa (patiromer) FDA Approval History - Drugs.com. Accessed December 18, 2020. https://www.drugs.com/history/veltassa.html
    1. Esposito P., Conti N.E., Falqui V. New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease. J Clin Med. 2020;9(8):2337. doi: 10.3390/jcm9082337. - DOI - PMC - PubMed

LinkOut - more resources